How Schiess was paid
$305,176 in total for 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Other | Total |
|---|---|---|---|---|
| Ralph SchiessFormer Interim Chief Executive Officer and Former Chief Science Officer | $265,176 | $40,000 | — | $305,176 |
| Neil CampbellFormer Chief Executive Officer | $5,481 | — | $158,333 | $163,814 |
| Bruce HarmonFormer Chief Financial Officer | $166,491 | — | $66,153 | $232,644 |
| Christian BrühlmannFormer Chief Strategy Officer | $265,176 | — | — | $265,176 |
| Karina FedaszInterim Chief Executive Officer and Interim Chief Financial Officer | $197,125 | — | — | $197,125 |
What changed and why
- $305KRalph Schiess received total compensation of $305,176 for serving as Interim Chief Executive Officer in fiscal 2024.
- $158KNeil Campbell received $158,333 in severance payments following his resignation as Chief Executive Officer.
- $66,153Bruce Harmon received $66,153 in severance upon his resignation as Chief Financial Officer.
- $197KKarina Fedasz was paid an annualized salary of $197,125 as Interim Chief Financial Officer.
- None of the named executive officers had outstanding equity awards at fiscal year-end.
Other Onconetix proxy statements
- 2026 proxy statement
Karina Fedasz paid $352,060 (+79% on the year).
Filed Oct 07, 2026
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.